Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Neuropharmacology. 2021 May 26;195:108623. doi: 10.1016/j.neuropharm.2021.108623

Figure 3.

Figure 3.

Effect of AM4113 treatment on the global protein levels of acetylated histone H3K9 (H3K9ac) and acetylated histone H3K14 (H3K14ac). (A) Representative photomicrographs of high magnification (scale bar = 50 μm) of H3K9ac gold-immunolabeling in central (CeA), medial (MeA) and basolateral (BLA) nuclei of amygdala of mice treated with either vehicle or AM4113 (1 mg/kg, i.p.). The location of these amygdaloid areas are shown by box at low magnification (scale bar = 1mm) images of amygdala of AM4113 or vehicle treated mice. (B) Bar graph shows levels of H3K9ac in CeA, MeA and BLA of AM4113 and vehicle treated mice (***p<0.001; n=6 in each group). (C) Representative photomicrographs of high magnification (scale bar = 50 μm) of H3K14ac gold-immunolabeling in CeA, MeA and BLA in mice treated with either vehicle or AM4113 (1 mg/kg). The locations of these amygdaloid areas are shown by box at low magnification (scale bar = 1mm) images of amygdala of AM4113 or vehicle treated mice. (D) Bar graph shows levels of H3K14ac in CeA, MeA and BLA following administration of AM4113 compared to vehicle group (**p<0.01; n=6 in each group). Individual values are shown with open circles and overall values are represented as mean ± SEM.